Cargando…

Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose–response meta-analysis

OBJECTIVES: To examine the association between coffee, including caffeinated and decaffeinated coffee, with hepatocellular carcinoma (HCC) and assess the influence of HCC aetiology and pre-existing liver disease. DESIGN: We performed a systematic review and meta-analysis. We calculated relative risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kennedy, Oliver John, Roderick, Paul, Buchanan, Ryan, Fallowfield, Jonathan Andrew, Hayes, Peter Clive, Parkes, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Open 2017
Materias:	Gastroenterology and Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730000/ https://www.ncbi.nlm.nih.gov/pubmed/28490552 http://dx.doi.org/10.1136/bmjopen-2016-013739

Ejemplares similares

Caffeinated Coffee, Decaffeinated Coffee and Endometrial Cancer Risk: A Prospective Cohort Study among US Postmenopausal Women
por: Giri, Ayush, et al.
Publicado: (2011)

Decaffeinated Coffee and Glucose Metabolism in Young Men
por: Greenberg, James A., et al.
Publicado: (2010)

Association of Coffee, Decaffeinated Coffee and Caffeine Intake from Coffee with Cognitive Performance in Older Adults: National Health and Nutrition Examination Survey (NHANES) 2011–2014.
por: Dong, Xue, et al.
Publicado: (2020)

Misclassification of coffee consumption data and the development of a standardised coffee unit measure
por: Poole, Robin, et al.
Publicado: (2019)

Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes
por: Poole, Robin, et al.
Publicado: (2017)

Effect of decaffeinated coffee on function and nucleotide metabolism in kidney
por: Rybakowska, I. M., et al.
Publicado: (2017)

Caffeinated and Decaffeinated Coffee Consumption and Risk of Type 2 Diabetes: A Systematic Review and a Dose-Response Meta-analysis
por: Ding, Ming, et al.
Publicado: (2014)

Acute Effects of Decaffeinated Coffee and the Major Coffee Components Chlorogenic Acid and Trigonelline on Glucose Tolerance
por: van Dijk, Aimée E., et al.
Publicado: (2009)

Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on incretin hormones
por: Olthof, Margreet R, et al.
Publicado: (2011)

Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial
por: Wedick, Nicole M, et al.
Publicado: (2011)

Effects of 16-Week Consumption of Caffeinated and Decaffeinated Instant Coffee on Glucose Metabolism in a Randomized Controlled Trial
por: Ohnaka, Keizo, et al.
Publicado: (2012)

The Impact of Instant Coffee and Decaffeinated Coffee on the Gut Microbiota and Depression-Like Behaviors of Sleep-Deprived Rats
por: Gu, Xinyi, et al.
Publicado: (2022)

All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study
por: Kennedy, Oliver J., et al.
Publicado: (2021)

COFFEE AND CAFFEINE
Publicado: (1958)

The effects of caffeinated and decaffeinated coffee on sex hormone-binding globulin and endogenous sex hormone levels: a randomized controlled trial
por: Wedick, Nicole M, et al.
Publicado: (2012)

Risk factors for malignant transformation of hepatocellular adenoma to hepatocellular carcinoma: protocol for systematic review and meta-analysis
por: Thevathasan, Tharusan, et al.
Publicado: (2021)

Effects of Caffeinated and Decaffeinated Coffee Consumption on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis of Data from Randomised Controlled Trials
por: Ramli, Nur Nadiah Syuhada, et al.
Publicado: (2021)

Trends in hepatocellular carcinoma research from 2008 to 2017: a bibliometric analysis
por: Miao, Yan, et al.
Publicado: (2018)

Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma
por: Kong, Fei, et al.
Publicado: (2020)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)
por: Brennan, Paul Noel, et al.
Publicado: (2021)

Trials in developing a nanoscale material for extravascular contrast-enhanced ultrasound targeting hepatocellular carcinoma
por: Wu, Size, et al.
Publicado: (2020)

Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization
por: Zhang, Jin-Xing, et al.
Publicado: (2022)

Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis
por: Thiele, Maja, et al.
Publicado: (2013)

Association between COX-2 gene polymorphisms and risk of hepatocellular carcinoma development: a meta-analysis
por: Lu, Si-Cong, et al.
Publicado: (2015)

Identification of an eight-gene signature for survival prediction for patients with hepatocellular carcinoma based on integrated bioinformatics analysis
por: Qiao, Guo-jie, et al.
Publicado: (2019)

Coordinative control of G2/M phase of the cell cycle by non-coding RNAs in hepatocellular carcinoma
por: Shi, Jun, et al.
Publicado: (2018)

KETOgenic diet therapy in patients with HEPatocellular adenoma: study protocol of a matched interventional cohort study
por: Oudmaijer, Christiaan Albert Johan, et al.
Publicado: (2022)

A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective study
por: Zhou, Zheyu, et al.
Publicado: (2023)

Glasgow Prognostic Score and modified Glasgow Prognostic Score and survival in patients with hepatocellular carcinoma: a meta-analysis
por: Lu, Lingling, et al.
Publicado: (2021)

Sub-milliSievert ultralow-dose CT colonography with iterative model reconstruction technique
por: Lambert, Lukas, et al.
Publicado: (2016)

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion
por: Weersink, Rianne A, et al.
Publicado: (2016)

Improving clinical outcomes of Barrett’s esophagus with high dose proton pump inhibitors and cryoablation
por: Snady, Harry
Publicado: (2023)

Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials
por: Kimer, Nina, et al.
Publicado: (2012)

Epigenetic identification of mitogen-activated protein kinase 10 as a functional tumor suppressor and clinical significance for hepatocellular carcinoma
por: Tang, Liping, et al.
Publicado: (2021)

Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation
por: Zhang, Dali, et al.
Publicado: (2022)

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma
por: Pang, Bing-yao, et al.
Publicado: (2022)

Different doses of prucalopride in treating chronic idiopathic constipation: a meta-analysis and Bayesian analysis
por: Yang, Tao, et al.
Publicado: (2021)

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
por: Zhang, Bo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ndjck6lb8711bfi5qbh3l3euj